gh stock Guide: Guardant Health Overview

GH (Guardant Health, Inc.) — Stock Overview

gh stock is the Nasdaq ticker symbol for Guardant Health, Inc., a precision oncology company that builds blood-based (“liquid biopsy”) genomic tests and data platforms. This article explains what gh stock represents, summarizes Guardant Health’s business and milestones, reviews recent FDA and commercial developments, presents market and financial metrics, and outlines the main investment considerations and trading factors. Readers will learn where to verify live data, which company results to watch each quarter, and how recent approvals and collaborations have affected gh stock momentum.

Note: This article is informational and not investment advice. All dated data cite sources where available.

Company profile

Guardant Health (NASDAQ: GH) focuses on blood-based oncology diagnostics and associated data analytics. Founded in 2012 and headquartered in Redwood City, California, the company develops tests that analyze circulating tumor DNA (ctDNA) and other biomarkers to support treatment selection, minimal residual disease (MRD) monitoring, and cancer screening. Guardant’s commercial portfolio targets clinical oncology customers (clinicians and hospitals), biopharma partners for clinical trials and drug development, and payer systems for broader access.

Key business lines include molecular profiling tests for advanced cancer (Guardant360 family), MRD and recurrence monitoring (GuardantINFINITY, Reveal), cancer screening (Shield), and data/software platforms that aggregate genomic and clinical signals for research and commercialization.

History and corporate milestones

• 2012: Guardant Health founded with a focus on developing ctDNA assays as alternatives or complements to tissue biopsy.
• 2018: Guardant360 received broader commercial uptake and the company expanded partnerships with biotech and pharma for companion diagnostic programs.
• 2018–2022: Series of collaborations and platform expansions; Guardant built data capabilities and pursued broader payer coverage.
• 2025–2026: Notable regulatory and commercial milestones accelerated the company’s market narrative:
  • As of January 20, 2026, according to Benzinga, the U.S. Food and Drug Administration (FDA) approved Guardant360 CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who may benefit from treatment with encorafenib (Braftovi) plus cetuximab and chemotherapy. This approval broadened the test’s companion diagnostic indications across multiple tumor types.
  • In early 2026, Guardant Health announced a multi-year collaboration with Merck to support development and commercialization of Merck’s oncology portfolio using the Guardant Infinity Smart platform (reported by Benzinga).
  • Guardant expanded reimbursement and payer coverage, and by late 2025 reported growing commercial test volumes and revenue gains.

These milestones have contributed to investor attention and influence gh stock price action.

Products and services

Guardant’s main product offerings address different clinical questions in oncology:

• Guardant360 / Guardant360 CDx: A comprehensive genomic profiling test using ctDNA from a blood draw. It identifies actionable genomic alterations for therapy selection and is used as a companion diagnostic in several tumor types.
• GuardantINFINITY: An ultra-sensitive MRD test designed for monitoring minimal residual disease in patients after curative-intent therapy.
• Shield: A screening product targeting early cancer detection in asymptomatic populations; commercial and clinical adoption is evolving.
• Reveal and other MRD-focused assays: Tools to detect recurrence risk and guide adjuvant therapy decisions.
• Data & software platforms: Guardant aggregates genomic and clinical data to support clinical trial enrollment, drug development partnerships, and real-world evidence generation.

Regulatory status varies by test and indication. Guardant360 CDx holds FDA companion diagnostic approvals for multiple therapies and tumor types. As of January 20, 2026, Guardant360 CDx’s new indication for BRAF V600E-mutant mCRC marked the platform’s 25th companion diagnostic indication, expanding clinical utility where tissue is unavailable or insufficient.

Stock and market information

Ticker: GH (commonly referenced as gh stock in search queries) Exchange: NASDAQ (U.S.) Trading hours: Regular U.S. market hours (typically 9:30 AM to 4:00 PM ET for NASDAQ listings) Identifiers: ISIN/CUSIP and other identifiers are published in SEC filings and exchange records; investors should verify via official filings or real-time market data services.

Common places to view quotes and charts include major financial portals and the company’s investor relations pages. For active trading, Bitget provides equity trading access and market data for U.S.-listed tickers—users should review Bitget’s product availability and account requirements.

Price history and performance

As of January 22, 2026, according to Benzinga, gh stock was trading at approximately $118.61. The stock had strengthened materially over the prior 12 months, with a reported 12-month increase of about 145.23% and the share price trading nearer to 52-week highs than lows. Technical indicators reported by Benzinga on that date included:

• Trading 10% above its 20-day simple moving average (SMA)
• Trading 37.8% above its 100-day SMA
• RSI around 68.24 (neutral-to-strong range)
• MACD above its signal line (bullish momentum indicator)

These technical signals indicated strong short-term momentum as of the cited date. Note that technical indicators change frequently and investors should verify live chart data before making decisions.

Key market statistics

Investors commonly track the following metrics for gh stock:

• Market capitalization: fluctuates with share price; verify current market cap from live quote pages or company filings as it changes intraday.
• Shares outstanding and float: reported in quarterly filings (10-Q/10-K) and useful for assessing dilution risk and liquidity.
• Average daily trading volume: helps assess liquidity and the cost of trading larger positions.
• Beta and volatility: Guardant’s beta and implied volatility data (from options markets) inform expected price movement relative to the market.
• Earnings per share (EPS) and revenue growth: fundamental drivers of valuation, though Guardant has had loss-making periods where P/E is not meaningful.

As of January 22, 2026, some high-level operational numbers reported by the company and cited in news coverage included preliminary Q4 2025 revenue of $280 million (up 39% year-over-year) and full-year 2025 sales of $981 million (up 33% year-over-year). These figures indicate revenue momentum driven by oncology testing and Shield screening volumes (reported by Guardant Health and cited in media coverage).

Analyst coverage and price targets

Sell-side analysts cover gh stock across major brokerage and research houses. As of January 22, 2026, Benzinga reported an average analyst price target near $87.25 and a consensus leaning toward Buy ratings among analysts referenced in that summary. Analysts commonly update earnings estimates, price targets, and sentiment ahead of key events such as quarterly reports or regulatory milestones.

Investors should note that analyst price targets are forward-looking estimates and reflect differing models, assumptions, and time horizons.

Financials and operating results

Guardant’s financial profile has been characterized by strong revenue growth driven by rising test volumes and expanded commercial partnerships, alongside investment in R&D, sales and marketing, and general administrative costs that have impacted profitability in prior periods.

• Revenue trends: Recent quarters showed double-digit revenue growth year-over-year, driven by increased adoption of Guardant360 tests, Shield screening, and expanded partnerships.
• Profitability: Historically unprofitable at the net income level, with losses narrowing or widening in different reporting periods based on investments and margins. Analysts refer to non-GAAP measures such as adjusted EBITDA to assess operating performance.
• Cash and balance sheet: Guardant maintains a cash position and may access capital markets if needed; investors track cash burn, operating cash flow, and financing activities disclosed in SEC filings.

Guardant released preliminary fourth quarter 2025 revenue of $280 million (up 39% YoY) and reported full-year 2025 sales of $981 million (up 33% YoY) as of company reporting in early 2026 (company release cited in media on January 2026). These figures were important catalysts for revenue-driven narratives around gh stock.

Quarterly and annual reporting

Investors should focus on the following items each quarter:

• Test volumes and mix: Number of commercial tests run, growth in Guardant360 vs. Shield vs. MRD products.
• Revenue by product line and geography: Which products drive growth and margin.
• Gross margins: Reflect test economics and pricing/reimbursement trends.
• Operating expenses: R&D intensity, sales and marketing investment, G&A.
• Guidance and cadence: Management’s outlook for next quarter or full-year, including any updates to reimbursement or regulatory assumptions.

Guardant typically issues quarterly results following a public schedule; for example, analysts were watching an upcoming earnings report scheduled for February 19, 2026 (as of January 22, 2026, according to Benzinga). For that upcoming report analysts expected a per-share loss of about $(0.61) and revenue near $273.83 million for the quarter.

Valuation metrics

Common valuation ratios used when evaluating gh stock include:

• Price-to-sales (P/S): Often used for growth companies with limited or negative earnings.
• Enterprise value to revenue (EV/Revenue): Helpful where capital structure matters.
• Forward revenue/earnings multiples: Based on analyst consensus forecasts.

Caveats: When a company reports net losses, P/E is not meaningful. Valuation comparisons should consider growth rates, margin expansion potential, and risks such as reimbursement and regulatory changes.

Investment thesis and market positioning

This section outlines both bullish and bearish considerations reported by market observers and analysts. The following is a balanced view summarizing typical lines of argument; it is not a recommendation.

Bullish arguments (growth drivers cited by supporters)

• Liquid biopsy adoption: As clinicians and pharma increasingly adopt blood-based genomic testing, Guardant’s scale and breadth of companion diagnostic indications can drive test volume growth.
• Platform effects and data assets: Large genomic datasets and partnerships (clinical and biopharma) can create differentiation and recurring revenue opportunities beyond individual tests.
• Regulatory momentum: FDA companion diagnostic approvals increase clinical legitimacy and broaden therapy-linked use cases. As of January 20, 2026, Guardant360 CDx’s new mCRC indication expanded the platform’s clinical coverage.
• Commercial traction: Reported revenue acceleration (Q4 2025 preliminary revenue of $280 million, full-year 2025 sales $981 million) signals demand and payer coverage expansion.

Bearish arguments (risks often cited by skeptics)

• Competition: Multiple companies pursue liquid biopsy and genomic profiling; competition can pressure pricing and market share.
• Reimbursement and regulatory risk: Changes in payer coverage, lab regulation, or unexpected FDA rulings could affect volumes and revenue.
• Execution risk: Scaling lab operations, international expansion, and commercialization of new products present operational challenges.
• Financial profile: Continued unprofitability or cash burn could necessitate capital raises, potentially diluting shareholders.

Competitive landscape

Guardant operates in a competitive environment that includes other molecular diagnostic firms, pathology labs, and biopharma service providers. Competitors and adjacent players focus on tissue-based and liquid biopsy testing, early detection, and oncology data services. Guardant’s competitive edge is often described as its combination of clinically validated tests, payer coverage, and a growing dataset that supports clinical and development use cases.

Corporate governance and management

Guardant’s executive team and board composition are detailed in company filings and investor relations materials. Investors monitor insider ownership, recent executive changes, and board-level developments for governance signals that can influence strategy and market confidence.

Partnerships, collaborations, and commercial strategy

Guardant pursues strategic collaborations across biopharma and clinical partners. As of early 2026, the company announced a multi-year collaboration with Merck to use the Guardant Infinity Smart platform to support Merck’s oncology portfolio (reported by Benzinga). Collaborations like this can drive revenue via companion diagnostic development, clinical trial screening, and co-commercialization agreements.

The company sells tests directly to clinicians and hospitals, partners with drug developers for companion diagnostic programs, and negotiates reimbursement agreements with Medicare and commercial payers to broaden access.

Regulatory, legal, and reimbursement environment

• FDA approvals: Guardant360 CDx has earned multiple companion diagnostic approvals. As of January 20, 2026, one notable FDA action expanded its companion diagnostic role in metastatic colorectal cancer for BRAF V600E mutations.
• Laboratory regulation: Guardant operates clinical laboratories subject to CLIA standards and other state and federal regulations; changes to lab policy could affect operations.
• Reimbursement: Coverage decisions from Medicare and major commercial payers materially affect test utilization. Guardant reported broadened payer coverage representing more than 300 million covered lives as of early 2026 (company and media reports).

Material legal or regulatory proceedings would be disclosed in SEC filings and major press coverage; investors should review recent 10-Q/10-K filings for up-to-date risk disclosures.

Risks and controversies

Major risks for Guardant and gh stock commonly flagged in filings and market commentary include:

• Technology and competitive risk: Alternative assays or competing platforms could reduce Guardant’s addressable market.
• Reimbursement contraction: Reduced coverage or unfavorable payment rates could slow adoption.
• Clinical adoption pace: Even clinically useful tests can take time to reach broad clinical adoption, especially for screening products.
• Financial execution: Continued operating losses or an inability to scale cost structure could necessitate fundraising.

Any material controversies, regulatory actions, or security incidents would be described in the company’s SEC disclosures and public statements.

Trading considerations

Liquidity and volatility: gh stock has shown periods of strong volatility that traders may exploit; average daily volume and bid-ask spreads are important when planning trades.

Options and derivatives: Options interest and implied volatility can indicate market expectations; these metrics change daily and are available via market data platforms.

Short interest: Monitor short interest and changes over reporting periods—higher short interest can amplify price moves on positive news.

Trading vs. long-term investing: Short-term traders often focus on technical indicators and news catalysts; long-term investors focus on revenue growth, regulatory approvals, and the data/network effects of Guardant’s platform. Bitget offers market access and tools for users who want to monitor gh stock—review Bitget’s trading products and compliance requirements locally before trading.

Tax and margin considerations: U.S. investors should consider tax implications for gains/losses and margin requirements when using leveraged products; consult a tax advisor for personal tax matters.

Notable events and recent developments

• As of January 20, 2026, according to Benzinga, the FDA approved Guardant360 CDx as a companion diagnostic for BRAF V600E-mutant metastatic colorectal cancer, supporting treatment decisions with encorafenib plus cetuximab and chemotherapy. The approval was supported by data from Pfizer’s Phase 3 BREAKWATER trial, which showed improvements in objective response rate, progression-free survival, and overall survival versus standard care.

• As of January 22, 2026, Benzinga reported that gh stock was trading at $118.61, up 2.47%, hitting a 52-week high and showing strong momentum indicators (20-day and 100-day SMA lifts, RSI ~68.24, MACD bullish). The Benzinga Edge scorecard cited Momentum as Bullish (Score: 97.64).

• Guardant reported preliminary Q4 2025 revenue of $280 million (up 39% YoY) and full-year 2025 sales of $981 million (up 33% YoY), driven by oncology testing and Shield screening volumes (company releases reported in early 2026 and cited in media).

• Guardant announced a multi-year collaboration with Merck to support development and commercialization of Merck’s oncology portfolio using Guardant Infinity Smart (reported in January 2026).

• Upcoming earnings: Analysts were tracking Guardant’s next earnings report on February 19, 2026, with consensus analyst estimates (as of Jan 22, 2026) expecting a loss per share near $(0.61) and revenue around $273.83 million for the quarter (Benzinga summary).

See also

• Liquid biopsy
• Precision oncology
• Companion diagnostics
• Oncology diagnostics companies and data platforms

References and further reading

Sources referenced in this article include major financial and news outlets and the company’s public disclosures. Notable mentions:

• Benzinga: Market coverage and technical indicators (reported January 2026)
• Company press releases and investor relations for Guardant Health (SEC filings for latest financials)
• FDA announcements and companion diagnostic approvals (public agency communications)
• Major financial portals for quotes, charts, and analyst consensus

As of January 22, 2026, specific figures and price data cited above were reported by Benzinga and company releases; readers should consult original filings and live market data for the latest information.

How to follow gh stock and Guardant Health updates

• Check Guardant Health’s investor relations materials and latest SEC filings for audited results and governance disclosures.
• Track real-time quotes and charts on financial platforms, and review analyst notes for estimate changes.
• Watch regulatory announcements (FDA) and major payer coverage news that can materially affect test adoption.
• Monitor partnerships and biopharma collaborations that signal commercial or clinical traction.

If you want to track or trade gh stock, Bitget provides market access and tools for equity monitoring—ensure your Bitget account is set up and compliant with local regulations before trading.

Trading checklist (what to monitor before a trade)

• Confirm current price, volume, and spreads on a live market feed.
• Review latest company press releases and SEC filings (10-Q/10-K) for financials and risk disclosures.
• Note upcoming catalysts: earnings dates (e.g., February 19, 2026), regulatory decisions, or major partnership announcements.
• Assess implied volatility (if trading options) and margin requirements.
• Ensure alignment with your risk tolerance and trading plan; this article is informational only and not investment advice.

Further exploration and next steps

For readers who want to dig deeper:

• Read Guardant Health’s most recent annual report and 10-Q filings for detailed financial statements and risk factors.
• Review peer-company filings and market analyses to compare valuation and growth profiles.
• Follow FDA and payer coverage announcements for changes to companion diagnostic indications and reimbursement status.

Explore Bitget’s platform to set up price alerts, monitor gh stock performance, and access market research tools. Always verify live prices and official filings before making trading or investment decisions.

Reporting dates and sources: As of January 20, 2026 and January 22, 2026, this summary references reporting by Benzinga and company disclosures including Guardant Health press releases and SEC filings.

This article aims to summarize public information about gh stock and Guardant Health as of the cited dates. It is not financial or investment advice. Verify current figures with official sources before acting.